56 results
FWP
LGVN
Longeveron Inc - Ordinary Shares
8 Apr 24
Free writing prospectus
8:45am
to patients and creating sustainable value for our shareholders.
Our lead investigational product is Lomecel-B™, which is derived from culture-expanded
424B5
LGVN
Longeveron Inc - Ordinary Shares
22 Dec 23
Prospectus supplement for primary offering
8:36am
product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced
424B5
i53ngdjohdrqn6y
13 Oct 23
Prospectus supplement for primary offering
6:07am
8-K
EX-99.1
9udfqpdi54p yy619va1
1 Sep 22
Regulation FD Disclosure
1:05pm
8-K
EX-99.1
asc peg1i1usfmjs
12 Aug 22
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2022 Financial Results
9:26am
8-K
EX-99.1
nuf7lyd3
13 May 22
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
9:50am
8-K
EX-99.1
0x1z qbwv8es49tgar
9 May 22
Longeveron Announces CEO Transition
4:26pm
S-3
pxomx8mx12m9jpb444l
5 Apr 22
Shelf registration
4:28pm
8-K
EX-99.1
sd414nx7lh
5 Apr 22
Longeveron Expands Executive Leadership Team; Appoints
4:01pm
8-K
EX-99.1
n5i519ah2d1pt4
11 Mar 22
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
8:45am
8-K
EX-99.1
yunze 7ea4onk8
17 Feb 22
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
4:02pm